Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02746744 (ClinicalTrials.gov)	May 2016	18/4/2016	RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.	RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. A Randomized Phase 3 Study Comparing Rituximab With Dimethyl Fumarate in Early Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome.	Multiple Sclerosis, Relapsing-Remitting	Drug: Rituximab;Drug: Dimethyl fumarate;Drug: Sodium Chloride solution	Anders Svenningsson	NULL	Completed	18 Years	50 Years	All	200	Phase 3	Sweden
2	NCT00764413 (ClinicalTrials.gov)	April 2009	1/10/2008	Chronotherapy in Acute Multiple Sclerosis (MS) Attack	Treatment With Methylprednisolone in Acute Exacerbations of Multiple Sclerosis: Enhanced Effect With Nighttime Treatment?	Multiple Sclerosis	Drug: methylprednisolone;Drug: Sodium chlorid	Sykehuset Innlandet HF	NULL	Terminated	18 Years	N/A	Both	57	N/A	Norway